Hyperphosphatemia in Chronic Kidney Disease: The Search for New Treatment Paradigms and the Role of Tenapanor

References

• Moe S, Drüeke T, Cunningham J, et al.; Kidney Disease: Improving Global Outcomes (KDIGO). Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: improving Global Outcomes (KDIGO). Kidney Int. 2006;69(11):1945–1953. doi:10.1038/sj.ki.5000414
   PubMed Web of Science ®Google Scholar
• Bellasi A, Mandreoli M, Baldrati L, et al. Chronic kidney disease progression and outcome according to serum phosphorus in mild-to-moderate kidney dysfunction. Clin J Am Soc Nephrol. 2011;6:883–891. doi:10.2215/CJN.07810910
   PubMed Web of Science ®Google Scholar
• Pavik I, Jaeger P, Ebner L, et al. Secreted Klotho and fgf23 in chronic kidney disease stage 1 to 5: a sequence suggested from a cross-sectional study. Nephrol Dial Transplant. 2013;28:352–359. doi:10.1093/ndt/gfs460
   PubMed Web of Science ®Google Scholar
• Bellasi A, Mangano M, Galassi A, Cozzolino M. CKD-MBD cardiovascular involvement and prognosis. Giorn Ital Nefr. 2017;34(Suppl 69):150–161.
   PubMedGoogle Scholar
• Faul C, Amaral AP, Oskouei B, et al. Fgf23 induces left ventricular hypertrophy. J Clin Invest. 2011;121:4393–4408.
   PubMed Web of Science ®Google Scholar
• Adragao T, Pires A, Lucas C, et al. A simple vascular calcification score predicts cardiovascular risk in haemodialysis patients. Nephrol Dial Transplant. 2004;19(6):1480–1488. doi:10.1093/ndt/gfh217
   PubMed Web of Science ®Google Scholar
• Górriz JL, Molina P, Cerverón MJ, et al. Vascular calcification in patients with nondialysis CKD over 3 years. Clin J Am Soc Nephrol. 2015;10(4):654–666. doi:10.2215/CJN.07450714
   PubMed Web of Science ®Google Scholar
• Zhou L, Fu P. The interpretation of KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Chin J Evidence Based Med. 2017;17(8):869–875.
   Google Scholar
• Thongprayoon C, Cheungpasitporn W, Mao MA, Sakhuja A, Erickson SB. Admission hyperphosphatemia increases the risk of acute kidney injury in hospitalized patients. J Nephrol. 2018;31(2):241–247. doi:10.1007/s40620-017-0442-6
   PubMed Web of Science ®Google Scholar
• Leaf DE, Wolf M. A physiologic-based approach to the evaluation of a patient with hyperphosphatemia. Am J Kidney Dis. 2013;61(2):330–336. doi:10.1053/j.ajkd.2012.06.026
   PubMed Web of Science ®Google Scholar
• Zheng WH, Yao Y, Zhou H, Xu Y, Huang HB. Hyperphosphatemia and outcomes in critically ill patients: a systematic review and meta-analysis. Front Med. 2022;9:1–11. doi:10.3389/fmed.2022.870637
   Google Scholar
• Cernaro V, Santoro D, Lucisano S, Nicocia G, Lacquaniti A, Buemi M. The future of phosphate binders: a perspective on novel therapeutics. Expert Opin Investig Drugs. 2014;23(11):1459–1463. doi:10.1517/13543784.2014.962652
   PubMed Web of Science ®Google Scholar
• Prasad A, Verghese D, Vijaya Rangan S, Sunadarajan N. Spontaneous tumour lysis secondary to gastric adenocarcinoma. BMJ Case Rep. 2024;17(1):e258369. doi:10.1136/bcr-2023-258369
   PubMedGoogle Scholar
• Molinaris V, Bianchetti MG, Milani GP, et al. Interferences in the measurement of circulating phosphate: a literature review. Clin Chem Lab Med. 2020;58(12):1971–1977. doi:10.1515/cclm-2020-0281
   PubMed Web of Science ®Google Scholar
• Ogata H, Sugawara H, Yamamoto M, Ito H. Phosphate and coronary artery disease in patients with chronic kidney disease. J Atheroscler Thromb. 2024;31(1):1–14. doi:10.5551/jat.RV22012
   PubMed Web of Science ®Google Scholar
• Vervloet M, Cozzolino M. Vascular calcification in chronic kidney disease: different bricks in the wall? Kidney Int. 2017;91(4):808–817. doi:10.1016/j.kint.2016.09.024
   PubMed Web of Science ®Google Scholar
• Cozzolino M, Gallieni M, Brancaccio D. Vascular calcification in uremic conditions: new insights into pathogenesis. Semin Nephrol. 2006;26(1):33–37. doi:10.1016/j.semnephrol.2005.06.008
   PubMed Web of Science ®Google Scholar
• Nikolajević J, Šabovič M. Inflammatory, metabolic, and coagulation effects on medial arterial calcification in patients with peripheral arterial disease. Int J Mol Sci. 2023;24(4):3132. doi:10.3390/ijms24043132
   PubMed Web of Science ®Google Scholar
• Ishimura E, Taniwaki H, Tabata T, et al. Cross-sectional association of serum phosphate with carotid intima-medial thickness in hemodialysis patients. Am J Kidney Dis. 2005;45(5):859–865. doi:10.1053/j.ajkd.2005.02.008
   PubMed Web of Science ®Google Scholar
• Jung J, Jeon-Slaughter H, Nguyen H, et al. Hyperphosphatemia and its relationship with blood pressure, vasoconstriction, and endothelial cell dysfunction in hypertensive hemodialysis patients. BMC Nephrol. 2022;23(1):291. doi:10.1186/s12882-022-02918-0
   PubMed Web of Science ®Google Scholar
• Okute Y, Shoji T, Shimomura N, et al. Serum phosphate as an independent factor associated with cholesterol metabolism in patients undergoing hemodialysis: a cross-sectional analysis of the DREAM cohort. Nephrol Dial Transplant. 2023;38(4):1002–1008. doi:10.1093/ndt/gfac222
   PubMed Web of Science ®Google Scholar
• Massy ZA, Merkling T, Wagner S, et al. Association of serum phosphate with efficacy of statin therapy in hemodialysis patients. Clin J Am Soc Nephrol. 2022;17(4):546–554. doi:10.2215/CJN.12620921
   PubMed Web of Science ®Google Scholar
• Eddington H, Hoefield R, Sinha S, et al. Serum phosphate and mortality in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2010;5(12):2251–2257. doi:10.2215/CJN.00810110
   PubMed Web of Science ®Google Scholar
• Molina P, Molina MD, Pallardó LM, et al. Disorders in bone-mineral parameters and the risk of death in persons with chronic kidney disease stages 4 and 5: the PECERA study. J Nephrol. 2021;34(4):1189–1199. doi:10.1007/s40620-020-00916-9
   PubMed Web of Science ®Google Scholar
• Zhou W, Zhang M, Ni Z. Acute phosphate nephropathy leading to graft failure. Clin Exp Nephrol. 2019;23(1):144–145. doi:10.1007/s10157-018-1608-9
   PubMed Web of Science ®Google Scholar
• Al Harbi SA, Al-Dorzi HM, Al Meshari AM, et al. Association between phosphate disturbances and mortality among critically ill patients with sepsis or septic shock. BMC Pharmacol Toxicol. 2021;22(1):30. doi:10.1186/s40360-021-00487-w
   PubMed Web of Science ®Google Scholar
• Black LP, Mohseni M, Shirazi E, et al. Association of early serum phosphate levels and mortality in patients with sepsis. West J Emerg Med. 2023;24(3):416–423. doi:10.5811/WESTJEM.58959
   PubMed Web of Science ®Google Scholar
• Liu Z, Li T, Du Y, Li C, Chong W. Both hypophosphatemia and hyperphosphatemia are associated with increased mortality in septic patients. Front Nephrol. 2022;2:1–16. doi:10.3389/fneph.2022.935288
   Google Scholar
• Yamada S, Tsuruya K, Taniguchi M, et al. Association between serum phosphate levels and stroke risk in patients undergoing hemodialysis: the Q-cohort study. Stroke. 2016;47(9):2189–2196. doi:10.1161/STROKEAHA.116.013195
   PubMed Web of Science ®Google Scholar
• Li T, Xie Y, Bowe B, Xian H, Al-Aly Z. Serum phosphorus levels and risk of incident dementia. PLoS One. 2017;12(2):e0171377.
   PubMed Web of Science ®Google Scholar
• Otobe Y, Hiraki K, Izawa KP, Sakurada T, Shibagaki Y. Relationship between serum inorganic phosphorus levels and cognitive decline over 2 years in older adults with pre-dialysis chronic kidney disease. Clin Exp Nephrol. 2020;24(3):286–287. doi:10.1007/s10157-019-01819-1
   PubMed Web of Science ®Google Scholar
• Beto J, Bhatt N, Gerbeling T, Patel C, Drayer D. Overview of the 2017 KDIGO CKD-MBD Update: practice Implications for Adult Hemodialysis Patients. J Ren Nutr. 2019;29(1):2–15. doi:10.1053/j.jrn.2018.05.006
   PubMed Web of Science ®Google Scholar
• D’Alessandro C, Piccoli GB, Cupisti A. The ”phosphorus pyramid”: a visual tool for dietary phosphate management in dialysis and CKD patients. BMC Nephrol. 2015;16(1):9. doi:10.1186/1471-2369-16-9
   PubMedGoogle Scholar
• Hutchison AJ. Oral phosphate binders. Kidney Int. 2009;75(9):906–914. doi:10.1038/ki.2009.60
   PubMed Web of Science ®Google Scholar
• Cernaro V, Longhitano E, Calabrese V, et al. Progress in pharmacotherapy for the treatment of hyperphosphatemia in renal failure. Expert Opin Pharmacother. 2023;24(15):1737–1746. doi:10.1080/14656566.2023.2243817
   PubMed Web of Science ®Google Scholar
• Tsuchiya K, Akihisa T. The Importance of Phosphate Control in Chronic Kidney Disease. Nutrients. 2021;13(5):1670. doi:10.3390/nu13051670
   PubMed Web of Science ®Google Scholar
• Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2017;7(1):1–59.
   PubMed Web of Science ®Google Scholar
• Block GA, Wheeler DC, Persky MS, et al. Effects of phosphate binders in moderate CKD. J Am Soc Nephrol. 2012;23(8):1407–1415. doi:10.1681/ASN.2012030223
   PubMed Web of Science ®Google Scholar
• Ogata H, Takeshima A, Ito H. An update on phosphate binders for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis: a review of safety profiles. Expert Opin Drug Saf. 2022;21(7):947–955. doi:10.1080/14740338.2022.2044472
   PubMed Web of Science ®Google Scholar
• Igbokwe IO, Igwenagu E, Igbokwe NA. Aluminium toxicosis: a review of toxic actions and effects. Interdiscip Toxicol. 2019;12(2):45–70.
   PubMedGoogle Scholar
• Cernaro V, Santoro D, Lacquaniti A, et al. Phosphate binders for the treatment of chronic kidney disease: role of iron oxyhydroxide. Int J Nephrol Renovasc Dis. 2016;9:11–19. doi:10.2147/IJNRD.S78040
   PubMed Web of Science ®Google Scholar
• Xu JP, Zeng RX, Liao PD, Zhang MZ. Effect of lanthanum carbonate on the progression of coronary artery calcification in hemodialysis patients: a meta-analysis of randomized controlled trials. Hemodial Int. 2022;26(2):223–233. doi:10.1111/hdi.12988
   PubMed Web of Science ®Google Scholar
• Ogata H, Fukagawa M, Hirakata H, et al. Effect of treating hyperphosphatemia with lanthanum carbonate vs calcium carbonate on cardiovascular events in patients with chronic kidney disease undergoing hemodialysis: the LANDMARK randomized clinical trial. JAMA. 2021;325(19):1946–1954.
   PubMed Web of Science ®Google Scholar
• Ogata H, Fukagawa M, Hirakata H, Kagimura T, Akizawa T; LANDMARK Investigators and Committees. Effect of lanthanum carbonate and calcium carbonate on the progression of coronary artery calcification among hemodialysis patients with vascular calcification risk: a randomized controlled trial. Clin Exp Nephrol. 2022;26(12):1223–1232. doi:10.1007/s10157-022-02270-5
   PubMed Web of Science ®Google Scholar
• Ruospo M, Palmer SC, Natale P, et al. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD). Cochrane Database Syst Rev. 2018;8(8):CD006023. doi:10.1002/14651858.CD006023.pub3
   PubMedGoogle Scholar
• Di Iorio B, Bellasi A, Russo D; INDEPENDENT Study Investigators. Mortality in kidney disease patients treated with phosphate binders: a randomized study. Clin J Am Soc Nephrol. 2012;7(3):487–493. doi:10.2215/CJN.03820411
   PubMed Web of Science ®Google Scholar
• Molina P, Molina MD, Carrero JJ, et al. Sevelamer use and mortality in people with chronic kidney disease stages 4 and 5 not on dialysis. J Clin Med. 2023;12(24):7631. doi:10.3390/jcm12247631
   PubMed Web of Science ®Google Scholar
• Basutkar RS, Varghese R, Mathew NK, Sankar Indira P, Viswanathan B, Sivasankaran P. Systematic review and meta-analysis of potential pleiotropic effects of sevelamer in chronic kidney disease: beyond phosphate control. Nephrology. 2022;27(4):337–354.
   PubMed Web of Science ®Google Scholar
• Vervloet MG, van Ballegooijen AJ. Prevention and treatment of hyperphosphatemia in chronic kidney disease. Kidney Int. 2018;93(5):1060–1072. doi:10.1016/j.kint.2017.11.036
   PubMed Web of Science ®Google Scholar
• Ikizler TA, Burrowes JD, Byham-Gray LD, et al. KDOQI clinical practice guideline for nutrition in CKD: 2020 update. Am J Kidney Dis. 2020;76(3 Suppl 1):S1–S107. Erratum in: Am J Kidney Dis. 2021;77(2):308.
   PubMed Web of Science ®Google Scholar
• Lee D-Y, Han SY, Lee K, et al. Association of a low protein diet with depressive symptoms and poor health-related quality of life in CKD. J Psychiatr Res. 2023;161:282–288. doi:10.1016/j.jpsychires.2023.02.032
   PubMed Web of Science ®Google Scholar
• Brown-Tortorici AR, Narasaki Y, You AS, et al. The interplay between dietary phosphorous, protein intake, and mortality in a prospective hemodialysis cohort. Nutrients. 2022;14(15):3070. doi:10.3390/nu14153070
   PubMed Web of Science ®Google Scholar
• Li J, Wang L, Han M, et al. The role of phosphate-containing medications and low dietary phosphorus-protein ratio in reducing intestinal phosphorus load in patients with chronic kidney disease. Nutr Diabetes. 2019;9(1):14. doi:10.1038/s41387-019-0080-2
   PubMed Web of Science ®Google Scholar
• Calvo MS, Moshfegh AJ, Tucker KL. Assessing the health impact of phosphorus in the food supply: issues and considerations. Adv Nutr. 2014;5(1):104–113. doi:10.3945/an.113.004861
   PubMed Web of Science ®Google Scholar
• Zhang W, Du Q, Xiao J, et al. Modification and validation of the phosphate removal model: a multicenter study. Kidney Blood Press Res. 2021;46(1):53–62. doi:10.1159/000511375
   PubMed Web of Science ®Google Scholar
• Cernaro V, Calderone M, Gembillo G, et al. Phosphate control in peritoneal dialysis patients: issues, solutions, and open questions. Nutrients. 2023;15(14):3161. doi:10.3390/nu15143161
   PubMed Web of Science ®Google Scholar
• Guedes M, Bieber B, Dasgupta I, et al. Serum phosphorus level rises in US hemodialysis patients over the past decade: a DOPPS special report. Kidney Med. 2022;5(2):100584. doi:10.1016/j.xkme.2022.100584
   PubMedGoogle Scholar
• Cozzolino M, Ketteler M, Wagner CA. An expert update on novel therapeutic targets for hyperphosphatemia in chronic kidney disease: preclinical and clinical innovations. Expert Opin Ther Targets. 2020;24(5):477–488. doi:10.1080/14728222.2020.1743680
   PubMed Web of Science ®Google Scholar
• Kalantar-Zadeh K, Forfang D, Bakris G, Martin KJ, Moe SM, Sprague SM. Managing phosphate burden in patients receiving dialysis: beyond phosphate binders and diet. Kidney360. 2023;4(11):1650–1656. doi:10.34067/KID.0000000000000262
   PubMedGoogle Scholar
• Kovesdy CP, Adebiyi A, Rosenbaum D, Jacobs JW, Quarles LD. Novel treatments from inhibition of the intestinal sodium-hydrogen exchanger 3. Int J Nephrol Renovasc Dis. 2021;14:411–420. doi:10.2147/IJNRD.S334024
   PubMed Web of Science ®Google Scholar
• Maruyama S, Marbury TC, Connaire J, Ries D, Maxwell W, Rambaran C. NaPi-IIb inhibition for hyperphosphatemia in CKD hemodialysis patients. Kidney Int Rep. 2020;6(3):675–684. doi:10.1016/j.ekir.2020.12.017
   PubMed Web of Science ®Google Scholar
• Larsson TE, Kameoka C, Nakajo I, et al. NPT-IIb inhibition does not improve hyperphosphatemia in CKD. Kidney Int Rep. 2017;3(1):73–80. doi:10.1016/j.ekir.2017.08.003
   PubMed Web of Science ®Google Scholar
• Katai K, Tanaka H, Tatsumi S, et al. Nicotinamide inhibits sodium-dependent phosphate cotransport activity in rat small intestine. Nephrol Dial Transplant. 1999;14(5):1195–1201. doi:10.1093/ndt/14.5.1195
   PubMed Web of Science ®Google Scholar
• Eto N, Miyata Y, Ohno H, Yamashita T. Nicotinamide prevents the development of hyperphosphataemia by suppressing intestinal sodium-dependent phosphate transporter in rats with adenine-induced renal failure. Nephrol Dial Transplant. 2005;20(7):1378–1384. doi:10.1093/ndt/gfh781
   PubMed Web of Science ®Google Scholar
• Ginsberg C, Ix JH. Nicotinamide and phosphate homeostasis in chronic kidney disease. Curr Opin Nephrol Hypertens. 2016;25(4):285–291. doi:10.1097/MNH.0000000000000236
   PubMed Web of Science ®Google Scholar
• Lenglet A, Liabeuf S, El Esper N, et al. Efficacy and safety of nicotinamide in haemodialysis patients: the NICOREN study. Nephrol Dial Transplant. 2017;32(5):870–879. doi:10.1093/ndt/gfx249
   PubMed Web of Science ®Google Scholar
• Malhotra R, Katz R, Hoofnagle A, et al. The effect of extended release niacin on markers of mineral metabolism in CKD. Clin J Am Soc Nephrol. 2018;13(1):36–44. doi:10.2215/CJN.05440517
   PubMed Web of Science ®Google Scholar
• Hill Gallant KM, Stremke ER, Trevino LL, et al. EOS789, a broad-spectrum inhibitor of phosphate transport, is safe with an indication of efficacy in a phase 1b randomized crossover trial in hemodialysis patients. Kidney Int. 2021;99(5):1225–1233. doi:10.1016/j.kint.2020.09.035
   PubMed Web of Science ®Google Scholar
• Hill Gallant KM, Vorland CJ. Intestinal phosphorus absorption: recent findings in translational and clinical research. Curr Opin Nephrol Hypertens. 2021;30(4):404–410. doi:10.1097/MNH.0000000000000719
   PubMed Web of Science ®Google Scholar
• King AJ, Siegel M, He Y, et al. Inhibition of sodium/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor reduces paracellular phosphate permeability. Sci Transl Med. 2018;10(456):eaam6474. doi:10.1126/scitranslmed.aam6474
   PubMed Web of Science ®Google Scholar
• Johansson S, Rosenbaum DP, Knutsson M, Leonsson-Zachrisson M. A phase 1 study of the safety, tolerability, pharmacodynamics, and pharmacokinetics of tenapanor in healthy Japanese volunteers. Clin Exp Nephrol. 2017;21(3):407–416. doi:10.1007/s10157-016-1302-8
   PubMed Web of Science ®Google Scholar
• Johansson S, Rosenbaum DP, Palm J, et al. Tenapanor administration and the activity of the H+ -coupled transporter PepT1 in healthy volunteers. Br J Clin Pharmacol. 2017;83(9):2008–2014. doi:10.1111/bcp.13313
   PubMed Web of Science ®Google Scholar
• Johansson S, Leonsson-Zachrisson M, Knutsson M, et al. Preclinical and healthy volunteer studies of potential drug-drug interactions between tenapanor and phosphate binders. Clin Pharmacol Drug Dev. 2017;6(5):448–456. doi:10.1002/cpdd.307
   PubMed Web of Science ®Google Scholar
• Johansson S, Rosenbaum DP, Ahlqvist M, et al. Effects of tenapanor on cytochrome P450-mediated drug-drug interactions. Clin Pharmacol Drug Dev. 2017;6(5):466–475. doi:10.1002/cpdd.346
   PubMed Web of Science ®Google Scholar
• Block GA, Rosenbaum DP, Leonsson-Zachrisson M, et al. Effect of tenapanor on serum phosphate in patients receiving hemodialysis. J Am Soc Nephrol. 2017;28(6):1933–1942. doi:10.1681/ASN.2016080855
   PubMed Web of Science ®Google Scholar
• Block GA, Rosenbaum DP, Yan A, Greasley PJ, Chertow GM, Wolf M. The effects of tenapanor on serum fibroblast growth factor 23 in patients receiving hemodialysis with hyperphosphatemia. Nephrol Dial Transplant. 2019;34(2):339–346. doi:10.1093/ndt/gfy061
   PubMed Web of Science ®Google Scholar
• Inaba M, Une Y, Ikejiri K, Kanda H, Fukagawa M, Akizawa T. Dose-response of tenapanor in patients with hyperphosphatemia undergoing hemodialysis in Japan-A Phase 2 randomized trial. Kidney Int Rep. 2021;7(2):177–188. doi:10.1016/j.ekir.2021.11.008
   PubMed Web of Science ®Google Scholar
• Block GA, Rosenbaum DP, Yan A, Chertow GM. Efficacy and safety of tenapanor in patients with hyperphosphatemia receiving maintenance hemodialysis: a randomized Phase 3 trial. J Am Soc Nephrol. 2019;30(4):641–652. doi:10.1681/ASN.2018080832
   PubMed Web of Science ®Google Scholar
• Pergola PE, Rosenbaum DP, Yang Y, Chertow GM. A randomized trial of tenapanor and phosphate binders as a dual-mechanism treatment for hyperphosphatemia in patients on maintenance dialysis (AMPLIFY). J Am Soc Nephrol. 2021;32(6):1465–1473. doi:10.1681/ASN.2020101398
   PubMed Web of Science ®Google Scholar
• Shigematsu T, Une Y, Ikejiri K, Kanda H, Fukagawa M, Akizawa T. Therapeutic effects of add-on tenapanor for hemodialysis patients with refractory hyperphosphatemia. Am J Nephrol. 2021;52(6):496–506. doi:10.1159/000516156
   PubMedGoogle Scholar
• Block GA, Bleyer AJ, Silva AL, et al. Safety and efficacy of tenapanor for long-term serum phosphate control in maintenance dialysis: a 52-week randomized Phase 3 trial (PHREEDOM). Kidney360. 2021;2(10):1600–1610. doi:10.34067/KID.0002002021
   PubMedGoogle Scholar
• Luo H, Feng J, Zhang Y, et al. Efficacy and safety of tenapanor in hemodialysis patients with hyperphosphatemia: a systematic review and meta-analysis of randomized placebo-controlled trials. Ther Apher Dial. 2023;27(5):839–847. doi:10.1111/1744-9987.14028
   PubMed Web of Science ®Google Scholar